- Home
- LSF vs NXTC Comparison
LSF vs NXTC Comparison
Compare LSF & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | NXTC |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 24.6M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | LSF | NXTC |
|---|---|---|
| Price | $2.09 | $11.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $12.00 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 95.9K | 55.1K |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,146,862.00 | N/A |
| Revenue This Year | $18.05 | N/A |
| Revenue Next Year | $17.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.73 | N/A |
| 52 Week Low | $2.07 | $2.69 |
| 52 Week High | $8.96 | $15.74 |
Technical Indicators
Market Signals| Indicator | LSF | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 30.55 | 52.95 |
| Support Level | $2.13 | $10.81 |
| Resistance Level | $2.52 | $12.49 |
| Average True Range (ATR) | 0.19 | 1.04 |
| MACD | 0.05 | -0.24 |
| Stochastic Oscillator | 10.39 | 22.87 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.